NEONC TECHNOLOGIES HOLDINGS (NTHI) Stock Price & Overview
NASDAQ:NTHI • US64051A1016
The current stock price of NTHI is 9.63 USD. Today NTHI is up by 4.9%. In the past month the price increased by 2.45%.
NTHI Key Statistics
- Market Cap
- 187.496M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.59
- Dividend Yield
- N/A
NTHI Stock Performance
NTHI Stock Chart
NTHI Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NTHI.
NTHI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NTHI. NTHI has a bad profitability rating. Also its financial health evaluation is rather negative.
NTHI Earnings
NTHI Forecast & Estimates
NTHI Groups
Sector & Classification
NTHI Financial Highlights
Over the last trailing twelve months NTHI reported a non-GAAP Earnings per Share(EPS) of -2.59. The EPS increased by 20.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1197.07% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NTHI Ownership
NTHI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.9 | 952.688B | ||
| JNJ | JOHNSON & JOHNSON | 21.05 | 594.495B | ||
| MRK | MERCK & CO. INC. | 22.23 | 297.42B | ||
| PFE | PFIZER INC | 8.86 | 151.126B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.24 | 124.629B | ||
| ZTS | ZOETIS INC | 18.34 | 55.496B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.14 | 27.407B | ||
| VTRS | VIATRIS INC | 5.86 | 17.144B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.23 | 12.37B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.391B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.298B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.453B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.408B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NTHI
Company Profile
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Company Info
NEONC TECHNOLOGIES HOLDINGS
23975 Park Sorrento, Suite 205
Calabasas CALIFORNIA US
Employees: 3
Phone: 13106637831
NEONC TECHNOLOGIES HOLDINGS / NTHI FAQ
Can you describe the business of NEONC TECHNOLOGIES HOLDINGS?
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
What is the current price of NTHI stock?
The current stock price of NTHI is 9.63 USD. The price increased by 4.9% in the last trading session.
Does NEONC TECHNOLOGIES HOLDINGS pay dividends?
NTHI does not pay a dividend.
How is the ChartMill rating for NEONC TECHNOLOGIES HOLDINGS?
NTHI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is NEONC TECHNOLOGIES HOLDINGS (NTHI) stock traded?
NTHI stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for NEONC TECHNOLOGIES HOLDINGS?
NEONC TECHNOLOGIES HOLDINGS (NTHI) operates in the Health Care sector and the Pharmaceuticals industry.